ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Mutations in the BCR-ABL1 kinase domain (KD) affect a significant proportion of CML patients and have been associated with primary or acquired (refractory disease following an initial response) resistances to TKIs [34–36].